Gender, age, and ethnicity in HIV vaccine-related research and clinical trials -: Report from a WHO-UNAIDS consultation, 26-28 August 2004.: Lausanne, Switzerland

被引:0
作者
Ackers, M
Alexander, SB
Allen, M
Bakari, M
Barsdorf, N
Barth-Jones, D
Birx, D
Cunningham, CK
DeCock, K
Francis, D
Fuchs, J
Hemelaar, J
Ireland, J
Kapoor, S
Karamov, E
Klein, M
Levendal, E
Lie, R
Macklin, R
Mathieson, B
Mathur, R
Mukengetshibaka, L
Nanvubya, A
Nakwagala, F
Nixon, S
Pantaleo, G
Pitisuttithum, P
Rogers, AS
dos Santos, VGV
Sheets, R
Safrit, J
Smit, T
Thorpe, P
Verlinde, C
Villafana, T
Warren, M
Xu, J
Mhalu, F
Thior, I
Amin, A
Bouësseau, MC
Chang, ML
Henri, M
Kieny, MP
Labelle, S
Malonza, I
Obermeyer, CM
Osmanov, S
Otani, J
Pagliusiuhe, S
机构
[1] Ctr Dis Control & Prevent, Atlanta, GA USA
[2] HIV Vaccine Trials Network, Washington, DC USA
[3] NIH, Bethesda, MD 20892 USA
[4] Muhimbili Univ, Coll Hlth Sci, Dar Es Salaam, Tanzania
[5] Univ KwaZulu Natal, Sch Psychol, Scottsville, South Africa
[6] Ctr Healthcare Effectiveness Res, Detroit, MI USA
[7] Dept Internal Med, Detroit, MI USA
[8] Walter Reed Army Inst Res, Silver Spring, MD USA
[9] Duke Univ, Med Ctr, Durham, NC 27706 USA
[10] Ctr Dis Control & Prevent, Nairobi, Kenya
[11] San Francisco Dept Publ Hlth, San Francisco, CA USA
[12] Univ Oxford, Sch Med, Oxford, England
[13] Elizabeth Glazer Pediat AIDS Fdn, Washington, DC USA
[14] Int AIDS Vaccine Initiat, New York, NY USA
[15] Minist Hlth, Moscow, Russia
[16] Canadian Network Vaccines & Immunotherapeut, Quebec City, PQ, Canada
[17] S African AIDS Vaccine Initiat, Tygerberg, South Africa
[18] Univ Bergen, Bergen, Norway
[19] Albert Einstein Coll Med, New York, NY USA
[20] Indian Council Med Res, New Delhi, India
[21] Canadian Int Dev Agcy, Quebec City, PQ, Canada
[22] Uganda Virus Res Inst, Entebbe, Uganda
[23] Canadian HIV AIDS Legal Network, Toronto, ON, Canada
[24] CHU Vaudois, CH-1011 Lausanne, Switzerland
[25] Mahidol Univ, Bangkok 10700, Thailand
[26] Ctr Referencia Ensaios Clin HIV AIDS, Rio De Janeiro, Brazil
[27] S African AIDS Vaccine Initiat, Tygerberg, South Africa
[28] Int AIDS Vaccine Initiat, New York, NY USA
[29] Botswana Harvard AIDS Inst, Gaborone, Botswana
[30] AIDS Vaccine Advocacy Coalit, New York, NY USA
[31] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China
[32] Muhmbili Univ, Coll Hlth Sci, Dar Es Salaam, Tanzania
关键词
HIV vaccines; clinical trials; vaccine efficacy; gender; age; ethnicity; ethics; regulatory aspects; community preparedness;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This report summarizes the presentations and recommendations from a consultation held in Lausanne, Switzerland (26-28 August 2004) organized by the joint World Health Organization (WHO) - United Nations Programme on HlV/AIDS (UNAIDS) HIV Vaccine Initiative. The consultation discussed issues related to gender, ethnicity, and age in HIV vaccine research and clinical trial recruitment. A special focus of the meeting was the participation of women and adolescents in clinical trials. Also discussed were the experiences and lessons from various research programs, trials, and studies in different countries. Implementing the recommendations from this meeting will require prioritization and active participation from the research community, funders of research, local and national governments, non-governmental organizations, and industry, as well as the individuals and communities participating in clinical trials. This report contains the collective views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the WHO. The contribution of the co-chairs (R. Macklin and F. Mhalu) and the rapporteurs (H. Lasher, M. Klein, M. Ackers, N. Barsdorf, A. Smith Rogers, E. Levendal, T. Villafana and M. Warren) during the consultation and in the preparation of this report is much appreciated. S. Labelle and J. Otani are also acknowledged and thanked for their efficient assistance in the preparation of the consultation and the report.
引用
收藏
页码:W7 / W28
页数:22
相关论文
共 18 条
[1]   POTENTIAL IMPACT OF LOW EFFICACY HIV-1 VACCINES IN POPULATIONS WITH HIGH-RATES OF INFECTION [J].
ANDERSON, RM ;
SWINTON, J ;
GARNETT, GP .
PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 1995, 261 (1361) :147-151
[2]   Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes [J].
Barouch, DH ;
Kunstman, J ;
Kuroda, MJ ;
Schmitz, JE ;
Santra, S ;
Peyerl, FW ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Gorgone, DA ;
Montefiori, DC ;
Lewis, MG ;
Wolinsky, SM ;
Letvin, NL .
NATURE, 2002, 415 (6869) :335-339
[3]  
Barth-Jones DC, 2000, PROCEEDINGS OF THE 2000 WINTER SIMULATION CONFERENCE, VOLS 1 AND 2, P1985, DOI 10.1109/WSC.2000.899196
[4]  
BARTHJONES DC, 2002, 2002 INT C HLTH SCI, P63
[5]  
BARTHOLOW BN, IN PRESS J ACQUIR IM
[6]   Economic evaluation of vaccination programs: The impact of herd-immunity [J].
Brisson, M ;
Edmunds, WJ .
MEDICAL DECISION MAKING, 2003, 23 (01) :76-82
[7]  
BUCHBINDER S, 2003, AIDS VACCINE NEW YOR
[8]   Risk behavior for HIV infection in participants in preventive HIV vaccine trials: A cautionary note [J].
Chesney, MA ;
Chambers, DB ;
Kahn, JO .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 16 (04) :266-271
[9]  
Edmunds WJ, 1999, STAT MED, V18, P3263, DOI 10.1002/(SICI)1097-0258(19991215)18:23&lt
[10]  
3263::AID-SIM315&gt